Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

References

• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. doi:10.1016/s0006-3223(99)00230-910686270
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Argolo FC, Araújo-de-Freitas L, et al. Rapid infusion of esketamine for unipolar and bipolar depres- sion: a retrospective chart review. Neuropsychiatr Dis Treat. 2017. doi:10.2147/NDT.S135623
   Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment- resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793. doi:10.1001/archgenpsychiatry.2010.9020679587
   PubMed Web of Science ®Google Scholar
• McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD011611.pub2
   Web of Science ®Google Scholar
• Szarmach J, Cubała WJ, Włodarczyk A, et al. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatr Danub. 2019 PMID: 3148878.
   Web of Science ®Google Scholar
• Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399–405. doi:10.1001/jamapsychiatry.2017.008028249076
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol 2019;22(10):616–630. doi:10.1093/ijnp/pyz039
   Google Scholar
• Traber DL, Wilson RD, Priano LL. Diferentiation of the cardiovascular efects of CI-581. Anesth Analg. 1968;47(6):769–778. doi:10.1213/00000539-196811000-000255749340
   PubMed Web of Science ®Google Scholar
• Miller R, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Young W. Miller’s Anesthesia. 8th ed. Philadelphia: Elsevier; 2015.
   Google Scholar
• Riva-Posse P, Reif CM, Edwards JA, et al. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Afect Disord. 2018;236:291–297. doi:10.1016/j.jad.2018.02.025
   PubMed Web of Science ®Google Scholar
• Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247–252. doi:10.4088/JCP.13m0885225271445
   PubMed Web of Science ®Google Scholar
• Poon SH, Sim K, Baldessarini RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol. 2015;13(5):592–604. doi:10.2174/1570159X1366615063017195426467409
   PubMed Web of Science ®Google Scholar
• Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. RESEARCH: validation of the massachusetts general hospital antidepressant treatment history questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322–325. doi:10.1111/j.1755-5949.2009.00102.x19769599
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol. 2009;24(3):133–138. doi:10.1097/YIC.0b013e328327761419318972
   PubMed Web of Science ®Google Scholar
• Young T. What exactly is a mood stabilizer? J Psychiatry Neurosci. 2004;29(2):87–88. PMCID: PMC383340.15069462
   PubMed Web of Science ®Google Scholar
• Zheng W, Zhou Y-L, Liu W-J, et al. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. J Affect Disord. 2020;275:38–43. doi:10.1016/j.jad.2020.06.02032658821
   PubMed Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry. 2019;76(9):893. doi:10.1001/jamapsychiatry.2019.1189
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–630. doi:10.1093/ijnp/pyz03931290965
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepre- ssant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428–438. doi:10.1176/appi.ajp.2019.1902017231109201
   PubMed Web of Science ®Google Scholar
• Short B, Fong J, Galvez V, Shelker W, Loo CK. Side- effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5:65–78. doi:10.1016/S2215-0366(17)30272-928757132
   PubMed Web of Science ®Google Scholar
• Doherty T, Wajs E, Melkote R, Miller J, Singh JB, Weber MA. Cardiac safety of esketamine nasal spray in treatment-resistant depression: results from the clinical development program. CNS Drugs. 2020;34(3):299–310. doi:10.1007/s40263-020-00699-431994024
   PubMed Web of Science ®Google Scholar
• Gastaldon C, Papola D, Ostuzzi G, Barbui C. Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiol Psychiatr Sci. 2020;29:e79, 1–4. doi:10.1017/S2045796019000751
   Web of Science ®Google Scholar
• Lu BY, Agapoff JR, Olson DJ, Williams SE, Roller A, Goeberta D. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series. J Affect Disord. 2020;262:40–42. doi:10.1016/j.jad.2019.10.05031706158
   PubMed Web of Science ®Google Scholar
• Peyrovian B, McIntyre RS, Phan L, et al. Registered clinical trials investigating ketamine for psychiatric disorders. J Psychiatr Res. 2020;127:1–12. doi:10.1016/j.jpsychires.2020.03.02032315806
   PubMed Web of Science ®Google Scholar